Tc-99m MAG3
Updates to Article Attributes
Body
was changed:
Tc-99m MAG3 (mercaptoacetyltriglycine) is one of thetechnetium radiopharmaceuticals used in renal imaging.
Characteristics
- photon energy: 140 KeV
- physical half life: 6 hours
- biological half life: 4 hours
- normal distribution: kidneys (100%)
- pharmacokinetics:
- uptake by tubular secretion (97%)
- first pass filtration 60%
- excretion: renal via
bothboth glomeruli infiltrationandand tubular excretion; hence, in paediatric patients and patients with poor renal function this test is considered superior to DTPA scan. - target organ: bladder
- miscellaneous facts
:- good quality images with renal insufficiency
- by giving
Captoprilcaptopril, MAG3 plasma clearance decreases in hypertensive patients with renal artery stenosis but increases in patients withoutRASrenal artery stenosis
Uses, doses and timings
- renal study
- adult dose: 8 mCi IV
- paediatric dose:
1000.10 mCi/kg (minimum:1 mCi; max: 50.4 mCi)5 - 60 sec flow study; then q5min for 25 min
-<p><strong>Tc-99m MAG3 (mercaptoacetyltriglycine)</strong> is one of the <a href="/articles/technetium-agents">technetium radiopharmaceuticals</a> used in renal imaging.</p><h4>Characteristics</h4><ul>- +<p><strong>Tc-99m MAG3 (mercaptoacetyltriglycine)</strong> is one of the <a href="/articles/technetium-agents">technetium radiopharmaceuticals</a> used in renal imaging.</p><h4>Characteristics</h4><ul>
-<li>excretion: renal via both glomeruli infiltration and tubular excretion; hence, in paediatric patients and patients with poor renal function this test is considered superior to <a href="/articles/gd-dtpa-labeled-albumin">DTPA </a>scan.</li>- +<li>excretion: renal via both glomeruli infiltration and tubular excretion; hence, in paediatric patients and patients with poor renal function this test is considered superior to <a href="/articles/gd-dtpa-labeled-albumin">DTPA </a>scan</li>
-<li>miscellaneous facts:<ul><li>good quality images with renal insufficiency</li></ul>- +<li>miscellaneous facts<ul>
- +<li>good quality images with renal insufficiency</li>
- +<li>by giving captopril, MAG3 plasma clearance decreases in hypertensive patients with <a href="/articles/renal-artery-stenosis">renal artery stenosis</a> but increases in patients without renal artery stenosis</li>
- +</ul>
-<li>by giving Captopril, MAG3 plasma clearance decreases in hypertensive patients with renal artery stenosis but increases in patients without RAS</li>-<li>paediatric dose: 100 mCi/kg (minimum: 1 mCi; max: 5 mCi)</li>- +<li>paediatric dose: 0.10 mCi/kg (minimum: 0.4 mCi) <sup>5</sup>
- +</li>
References changed:
- 5. Treves ST, Parisi MT, Gelfand MJ. Pediatric radiopharmaceutical doses: new guidelines. Radiology. 2011;261 (2): 347-9. <a href="http://dx.doi.org/10.1148/radiol.11110449">doi:10.1148/radiol.11110449</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/22012901">Pubmed citation</a><span class="auto"></span>
Sections changed:
- Imaging Technology
Unable to process the form. Check for errors and try again.